SkyView Investment Advisors’s Estrella Immunopharma ESLA Stock Holding History

SkyView Investment Advisors’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-125,000	Closed	-$1.35M	–	646
2023 Q2	$1.35M	Hold	125,000	–	–	0.34%	88
2023 Q1	$1.33M	Hold	125,000	–	–	0.31%	78
2022 Q4	$1.29M	Buy	+125,000	New	+$1.27M	0.39%	75

Other funds holding ESLA

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

SkyView Investment Advisors's ESLA Position: Q3 2023 in Review

SkyView Investment Advisors sold out of Estrella Immunopharma (ESLA) in Q3 2023, closing a stake of 125,000 shares — an estimated $1.35M sold.

SkyView Investment Advisors first reported a position in ESLA in Q4 2022 and held it in 3 quarters. The position peaked at $1.35M in Q2 2023. 3 funds tracked by Wall St. Rank hold ESLA as of Q3 2023.

SkyView Investment Advisors reported no remaining Estrella Immunopharma position as of Q3 2023 after selling out during the quarter.
SkyView Investment Advisors sold 125,000 Estrella Immunopharma shares in Q3 2023, an estimated $1.35M.
SkyView Investment Advisors first reported a position in Estrella Immunopharma in Q4 2022 and held it in 3 quarters.
SkyView Investment Advisors's Estrella Immunopharma position peaked at $1.35M in Q2 2023.
3 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2023.

Based on SkyView Investment Advisors's 13F filing for Q3 2023, filed 17 Nov 2023.